Isomorphic Labs Raises $5 Billion Series C Led by Greenoaks and Sequoia, With Andreessen Horowitz Joining

Isomorphic Labs, the drug design company founded in 2021 to build on Google DeepMind’s AlphaFold work, announced on 17 November 2026 that it had raised a $5 billion Series C round. Greenoaks and Sequoia Capital co-led the round, and Andreessen Horowitz joined as a new investor, according to TheNextWeb’s report of the announcement.
Investors
Existing investors Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund also took part. The company says Alphabet continued its significant investment. The company said investors oversubscribed the round.
Use of funds
The company says it is scaling its drug design engine, IsoDDE, and its pipeline of AI-designed therapeutic candidates. TheNextWeb reports that Demis Hassabis, the company’s chief executive, spoke to Bloomberg about using the money to accelerate clinical trials, and said: “What we’re trying to build is a platform to do hundreds of drugs a year.” Lens did not read the Bloomberg article, so these remarks come from TheNextWeb’s account.
Valuation
The company did not disclose a valuation. Bloomberg had reported talks at about $50 billion before the round was announced; Lens could not confirm that figure. TheNextWeb reports that the round follows a $2.1 billion raise in May 2026, about six months earlier.
Sources and notes
Read in full: TheNextWeb, 17 November 2026, which reports the announcement. Lens also read the company’s announcement page, Isomorphic Labs, but the text it returned gave the investors and amount without a valuation or executive quotes. Lens did not open the Bloomberg report. The company’s valuation was not disclosed.
Image: Demis Hassabis, the company’s chief executive, at an earlier event. It is not from the funding announcement. Photo by Alain Herzog, CC BY-SA 4.0, via Wikimedia Commons.

